Navigation Links
EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD
Date:11/5/2007

OAK BROOK, Ill., Nov. 5 /PRNewswire/ -- EPI-Q, Inc., a consulting firm providing outcomes research and health economics services to the global biopharmaceutical and healthcare industries, announces the addition of Anthony J. Vita, MD, MPH and Peter Herout, PharmD to their team of clinical professionals. The specialized background of these two practitioners will augment the capabilities EPI-Q is able to offer directly to those clients seeking to enhance the clinical outcomes and cost-effectiveness of patient care.

Both Dr. Herout and Dr. Vita will be responsible for providing clinical support and managing projects within their fields of clinical expertise. "Peter has significant expertise in critical care and cardiology adding to our ability to provide services to hospitals and managed care in both of these important areas. Anthony has clinical skills in mental health, a therapeutic category in which EPI-Q's business is rapidly expanding and his public health training provides additional depth to our methods group," stated EPI-Q President, Mark Jewell.

Dr. Herout has over 8 years experience as a clinical pharmacist. He has spent the majority of his professional career caring for a variety of critically ill patient populations. His most recent practice and research interests have included severe trauma, cardiothoracic surgery, sepsis, glycemic control, infectious diseases, renal replacement therapy, and nutrition support. Before joining EPI-Q, Dr. Herout spent 4 years with Advocate Christ Medical Center in Oak Lawn, Illinois. His contributions to the medical literature have included articles published in Critical Care Medicine and the American Journal of Health-System Pharmacy. He received his PharmD degree from the University of Illinois at Chicago, and completed one-year ASHP-accredited residencies in Pharmacy Practice and Critical Care.

Prior to joining EPI-Q, Dr. Vita worked as a resident physician at the University of Chicago, Department of Psychiatry for 3 years. He has also practiced in a variety of hospital settings including ICU, CCU, general medicine, general pediatrics, pediatric ICU, obstetrics, and neurology. Among the journals publishing Dr. Vita's works are The New England Journal of Medicine, The Journal of Pharmacology and Experimental Therapeutics, and The American Journal of Physiology. Dr. Vita received his Doctor of Medicine degree from Stanford University and Master of Public Health degree from Harvard University.

EPI-Q, Inc. (http://www.epi-q.com) provides life sciences companies and healthcare providers and payer organizations with evidence-based solutions that elucidate the value of medical technology and improve health outcomes and cost-effectiveness. EPI-Q's professionals have extensive expertise in medicine, pharmacy, epidemiology, biostatistics, economics, business and healthcare administration. In addition, many of these experts maintain academic affiliations, publish and present frequently on issues pertaining to quality improvement and outcomes management.

Contacts:

Mark Jewell, PhD Andrew M. Baker

President Vice President - Business Development

EPI-Q, Inc. EPI-Q, Inc.

Tel: 630.570.5505 Tel: 914.358.3264

Fax: 630.570.5506 Fax: 914.358.3265

Email: mark.jewell@epi-q.com Email: drew.baker@epi-q.com


'/>"/>
SOURCE EPI-Q, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/28/2017)... ... ... Executive search firm, Slone Partners, announces the placement of ... distinguished life sciences expert with a proven track record in strategic global business ... of services related to laboratory testing and analysis for the pharmaceutical, medical device, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the fight against cancer, autoimmune disease and more through a single-cell precision engineering ... and proteomics analysis platform developed in the laboratory of Dr. James Heath ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... generally produce small, heterogeneous samples with limited tumor content in a large background ... be resolved, such as the need for reliable detection of low abundance somatic ...
Breaking Biology Technology:
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
Breaking Biology News(10 mins):